NetraMark Holdings (TSE:AIAI) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NetraMark Holdings has signed a pilot collaboration agreement with a top pharmaceutical company to enhance the development of new autoimmune disorder treatments using its advanced AI technology. The collaboration will leverage NetraAI to analyze genetic data and refine patient subtypes, aiming to unlock novel insights and improve clinical trial outcomes. This partnership underscores NetraMark’s commitment to advancing precision medicine and driving innovation in treatment strategies.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.